<p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）的股票在周一由 Wells Fargo &amp; Company 的股票研究人员在一份发给投资者的报告中重申了 “持平” 评级，Benzinga 报道。他们目前对该股票的目标价为 42.00 美元，高于之前的 35.00 美元目标价。Wells Fargo &amp; Company 的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 6.03%。</p>
<ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
<p>其他几家研究公司也最近对 CNTA 发表了看法。Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Centessa Pharmaceuticals 股票的 “卖出（d-）” 评级。Guggenheim 在 4 月 2 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Wolfe Research 在 3 月 31 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “跑赢大盘” 下调至 “持有”。Stephens 在 3 月 31 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，Leerink Partners 在 4 月 1 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “跑赢大盘” 下调至 “持有”，并将其目标价从 36.00 美元上调至 40.00 美元。四位投资分析师对该股票给予了买入评级，九位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为 40.70 美元。</p>
<p><strong>阅读我们关于 Centessa Pharmaceuticals 的最新报告</strong></p>
<h2>Centessa Pharmaceuticals 股票表现</h2>
<p>Centessa Pharmaceuticals 的股票在周一的午盘交易中下跌 0.05 美元，达到 39.61 美元。该股票的交易量为 819,934 股，而其平均交易量为 2,431,604 股。Centessa Pharmaceuticals 的 12 个月低点为 10.95 美元，12 个月高点为 40.26 美元。该公司的 50 日移动平均价格为 30.15 美元，200 日移动平均价格为 26.76 美元。该公司的市值为 61.2 亿美元，市盈率为-26.95，贝塔值为 1.25。该公司的速动比率为 8.57，流动比率为 8.57，债务与股本比率为 0.21。</p>
<p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）最后一次公布季度财报是在 3 月 31 日。该公司报告每股收益（EPS）为-0.48 美元，低于分析师的共识预期-0.38 美元，差距为 0.10 美元。整体来看，研究分析师预测 Centessa Pharmaceuticals 在当前财政年度的每股收益为-1.6 美元。</p>
<h2>Centessa Pharmaceuticals 的内部买卖</h2>
<p>在其他 Centessa Pharmaceuticals 的新闻中，内部人士 Gregory M. Weinhoff 在 3 月 13 日的交易中出售了 73,196 股该公司的股票。该股票以平均价格 26.33 美元出售，总交易额为 1,927,250.68 美元。交易完成后，内部人士持有 65,925 股公司股票，价值约为 1,735,805.25 美元。这笔交易代表了他们持股的 52.61% 的减少。该出售在向 SEC 的备案中披露，可以通过此链接访问。此外，内部人士 Iqbal J. Hussain 在 2 月 2 日的交易中出售了 38,951 股该公司的股票。这些股票以平均价格 25.15 美元出售，总价值为 979,617.65 美元。交易完成后，内部人士持有 57,645 股公司股票，价值为 1,449,771.75 美元。这笔交易代表了他们持股的 40.32% 的减少。该出售的 SEC 备案提供了更多信息。在过去 90 天内，内部人士出售了 349,073 股公司股票，价值为 9,429,412 美元。当前 7.09% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。TD Waterhouse Canada Inc.在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 25,000 美元。Caitong International Asset Management Co. Ltd 在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 36,000 美元。T. Rowe Price Investment Management Inc.在第四季度将其在 Centessa Pharmaceuticals 的持股增加了 7,580.0%。T. Rowe Price Investment Management Inc.现在拥有 1,536 股该公司的股票，价值 39,000 美元，此前在上个季度又购买了 1,516 股。Wells Fargo &amp; Company MN 在第四季度将其在 Centessa Pharmaceuticals 的持股增加了 42.4%。Wells Fargo &amp; Company MN 现在拥有 3,387 股该公司的股票，价值 85,000 美元，此前在上个季度又购买了 1,008 股。最后，Knott David M Jr 在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值 100,000 美元。82.01% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Centessa Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Centessa Pharmaceuticals plc 是一家全球临床阶段生物制药公司，专注于在多个疾病领域发现和开发创新疗法。该公司运营一个模块化的研发网络，将一系列独立的专业研究实体整合在一个企业框架下。该结构旨在加速决策和资源分配，同时利用每个治疗领域的深厚科学专业知识。</p>
<p>Centessa 的产品线涵盖肿瘤学、免疫学、神经科学、心血管和代谢疾病，以及罕见遗传疾病。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Centessa Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
<p>在考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
<p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CNTA

<p>富国银行（Wells Fargo & Company）重申了对 Centessa Pharmaceuticals（NASDAQ:CNTA）的 “持平” 评级，并将其目标价格从 35.00 美元上调至 42.00 美元，显示出 6.03% 的潜在上涨空间。目前，该股票被分析师评为 “持有”，平均目标价格为 40.70 美元。最近的交易中，股票价格为 39.61 美元，12 个月的价格区间为 10.95 美元至 40.26 美元。内部交易活动显示出显著的销售，内部人士持有的股份占比为 7.09%。机构投资者近期在买卖股票方面也表现活跃</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report)'s stock had its &#34;equal weight&#34; rating reaffirmed by equities researchers at Wells Fargo &amp; Company in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 price target on the stock, up from their prior price target of $35.00. Wells Fargo &amp; Company's price objective would indicate a potential upside of 6.03% from the company's previous close.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）的股票在周一由 Wells Fargo &amp; Company 的股票研究人员在一份发给投资者的报告中重申了 “持平” 评级，Benzinga 报道。他们目前对该股票的目标价为 42.00 美元，高于之前的 35.00 美元目标价。Wells Fargo &amp; Company 的目标价表明，相较于公司之前的收盘价，潜在上涨幅度为 6.03%。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>关注这只生物科技股票，它仍然具有巨大的潜在上涨空间</li>
</ul>
</div><p>Several other research firms have also recently weighed in on CNTA. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Guggenheim cut shares of Centessa Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, April 2nd. Wolfe Research cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Stephens cut shares of Centessa Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Finally, Leerink Partners cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus target price of $40.70.</p>
<div class="lb-trans"><p>其他几家研究公司也最近对 CNTA 发表了看法。Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Centessa Pharmaceuticals 股票的 “卖出（d-）” 评级。Guggenheim 在 4 月 2 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Wolfe Research 在 3 月 31 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “跑赢大盘” 下调至 “持有”。Stephens 在 3 月 31 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，Leerink Partners 在 4 月 1 日的研究报告中将 Centessa Pharmaceuticals 的股票评级从 “跑赢大盘” 下调至 “持有”，并将其目标价从 36.00 美元上调至 40.00 美元。四位投资分析师对该股票给予了买入评级，九位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “持有”，共识目标价为 40.70 美元。</p>
</div><p><strong>Read Our Latest Report on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Centessa Pharmaceuticals 的最新报告</strong></p>
</div><h2>Centessa Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票表现</h2>
</div><p>Centessa Pharmaceuticals stock traded down $0.05 during midday trading on Monday, reaching $39.61. The stock had a trading volume of 819,934 shares, compared to its average volume of 2,431,604. Centessa Pharmaceuticals has a 12 month low of $10.95 and a 12 month high of $40.26. The firm's 50-day moving average price is $30.15 and its 200 day moving average price is $26.76. The firm has a market capitalization of $6.12 billion, a PE ratio of -26.95 and a beta of 1.25. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals 的股票在周一的午盘交易中下跌 0.05 美元，达到 39.61 美元。该股票的交易量为 819,934 股，而其平均交易量为 2,431,604 股。Centessa Pharmaceuticals 的 12 个月低点为 10.95 美元，12 个月高点为 40.26 美元。该公司的 50 日移动平均价格为 30.15 美元，200 日移动平均价格为 26.76 美元。该公司的市值为 61.2 亿美元，市盈率为-26.95，贝塔值为 1.25。该公司的速动比率为 8.57，流动比率为 8.57，债务与股本比率为 0.21。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（纳斯达克代码：CNTA - 获取免费报告）最后一次公布季度财报是在 3 月 31 日。该公司报告每股收益（EPS）为-0.48 美元，低于分析师的共识预期-0.38 美元，差距为 0.10 美元。整体来看，研究分析师预测 Centessa Pharmaceuticals 在当前财政年度的每股收益为-1.6 美元。</p>
</div><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的内部买卖</h2>
</div><p>In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company's stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Centessa Pharmaceuticals 的新闻中，内部人士 Gregory M. Weinhoff 在 3 月 13 日的交易中出售了 73,196 股该公司的股票。该股票以平均价格 26.33 美元出售，总交易额为 1,927,250.68 美元。交易完成后，内部人士持有 65,925 股公司股票，价值约为 1,735,805.25 美元。这笔交易代表了他们持股的 52.61% 的减少。该出售在向 SEC 的备案中披露，可以通过此链接访问。此外，内部人士 Iqbal J. Hussain 在 2 月 2 日的交易中出售了 38,951 股该公司的股票。这些股票以平均价格 25.15 美元出售，总价值为 979,617.65 美元。交易完成后，内部人士持有 57,645 股公司股票，价值为 1,449,771.75 美元。这笔交易代表了他们持股的 40.32% 的减少。该出售的 SEC 备案提供了更多信息。在过去 90 天内，内部人士出售了 349,073 股公司股票，价值为 9,429,412 美元。当前 7.09% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock worth $39,000 after acquiring an additional 1,516 shares in the last quarter. Wells Fargo &amp; Company MN raised its holdings in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo &amp; Company MN now owns 3,387 shares of the company's stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。TD Waterhouse Canada Inc.在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 25,000 美元。Caitong International Asset Management Co. Ltd 在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值约为 36,000 美元。T. Rowe Price Investment Management Inc.在第四季度将其在 Centessa Pharmaceuticals 的持股增加了 7,580.0%。T. Rowe Price Investment Management Inc.现在拥有 1,536 股该公司的股票，价值 39,000 美元，此前在上个季度又购买了 1,516 股。Wells Fargo &amp; Company MN 在第四季度将其在 Centessa Pharmaceuticals 的持股增加了 42.4%。Wells Fargo &amp; Company MN 现在拥有 3,387 股该公司的股票，价值 85,000 美元，此前在上个季度又购买了 1,008 股。最后，Knott David M Jr 在第四季度购买了 Centessa Pharmaceuticals 的新股份，价值 100,000 美元。82.01% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&amp;D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家全球临床阶段生物制药公司，专注于在多个疾病领域发现和开发创新疗法。该公司运营一个模块化的研发网络，将一系列独立的专业研究实体整合在一个企业框架下。该结构旨在加速决策和资源分配，同时利用每个治疗领域的深厚科学专业知识。</p>
</div><p>Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.</p>
<div class="lb-trans"><p>Centessa 的产品线涵盖肿瘤学、免疫学、神经科学、心血管和代谢疾病，以及罕见遗传疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Centessa Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Centessa Pharmaceuticals 吗？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Centessa Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Centessa Pharmaceuticals 并不在名单上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Centessa Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Centessa Pharmaceuticals' (CNTA) Equal Weight Rating Reaffirmed at Wells Fargo & Company

Market Beat

Centessa Pharmaceuticals

富国银行

Toronto Dominion Bank

普信金融

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

富国银行公司重申了对 Centessa Pharmaceuticals（CNTA）的持平评级